Clinical Performance Partners Launches New Web Site
Clinical Performance Partners, Inc. (CPP) announces the launch of their website (www.clinicalperformancepartners.com).
Contact: Beth Harper FOR IMMEDIATE RELEASE
Phone: 817-946-4892
Email: bharper@clinicalperformancepartners.com
CLINICAL PERFORMANCE PARTNERS LAUNCHES NEW WEBSITE
KELLER, TX June 19, 2008 – Clinical Performance Partners, Inc. (CPP) announces the launch of their website (www.clinicalperformancepartners.com).
“In addition to establishing a web presence for the company, the goal of the website is to serve as a valuable resource to the industry for all things related to patient recruitment / retention and site relationship management” says Beth Harper, President of Clinical Performance Partners, Inc.
The website features a listing of patient recruitment service providers with links to their websites. In addition, viewers can search for articles related to patient recruitment and site relationship management, as well as download sample tools and templates developed by CPP, Inc.
“As a long-time champion and advocate for educating the industry on the process and practice of patient recruitment, I am delighted to share my interest, experience and resources as we all strive to overcome the chronic challenges associated with patient recruitment” says Harper.
“Predicting, managing, supporting and enhancing site performance in clinical trials is not only our mission by my personal passion” notes Harper who celebrates some 25 years of “in the trenches” healthcare and clinical research experience this year.
About Clinical Performance Partners - CPP is a consulting firm dedicated to designing and implementing innovative and practical solutions for improving site performance and accelerating clinical trials results for the Life Sciences Industry. www.clinicalperformancepartners.com
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
